FX.co ★ Organovo Appoints Norman Staskey As CFO

Organovo Holdings, Inc. (ONVO), a clinical-stage biotechnology company specializing in pioneering treatments for inflammatory bowel disease, announced on Monday the appointment of Norman Staskey as its new Chief Financial Officer (CFO). Staskey brings experience from Danforth Advisors, where he has been delivering CFO services since 2021 to clients such as Azitra, Inc. As of the latest update, ONVO's stock is experiencing a rise, trading at $0.48, which marks an increase of 7.15 percent or $0.032 on the Nasdaq.